CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cilo Cybin Holdings Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cilo Cybin Holdings Ltd
7 Sterling Street
The Point Office Park Unit C1
CENTURION, South Africa Ticker: CCCCCC
Business Summary
Cilo Cybin Holdings Limited is a South Africa-based biotech investment company. The Company's main operations are identifying viable investments in biotech, biohacking and pharmaceutical businesses. It is focused on supplying Good Manufacturing Practices (GMP) medical cannabis products, including GMP Cannabidiol (CBD), CBG, CBN isolates and GMP delta-9-tetrahydrocannabinol (THC), and CBD distillates. Its products include bulk products, THC distillate, CBD isolate, house brand and finished products. It specializes in supplying medical-grade cannabis flower and final products, using a cold ethanol extraction process with input materials. It caters to both bulk packaging and customized specifications, suitable for various applications, including vape products, oils, and edible formulations. It also offers cannabis active pharmaceutical ingredients (API) products. Its products can be used in various applications, such as vape products, tinctures, edibles, and topicals.
(Source: 10KSB40)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20243/31/2024Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Seng KongTham 54 2/5/2024 2/5/2024
Chief Executive Officer, Executive Director GabrielTheron 41 2/23/2022 2/23/2022
Chief Financial Officer, Finance Director, Executive Director H.B.Aukamp 72 2/23/2022 2/23/2022
4 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 71,017,906 (As of 6/25/2024)
Stock Exchange: JNB
Email Address: hello@cilocybin.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024